3 results
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
The aim of the present *proof-of-principle* study is to test in patients suffering from AIHA whether co-administration of C1-inh improves the recovery of RBC transfusion by the inhibition of the activation of the classical pathway of complement. In…
The purpose of this study is to compare STZ vs everolimus as first line treatment for advanced pNET and elucidate which sequence of STZ based chemotherapy and the mTOR inhibitor, everolimus, gives better results in terms of PFS in well…